Drug cocktail

10 October 2017 By John Foley, Neil Unmack

The $215 bln U.S. drugmaker is preparing to detach its consumer-goods unit, and its British rival is a logical owner. Folding the Advil maker into GlaxoSmithKline’s existing venture with Novartis would be logical, provided CEO Emma Walmsley can whip the business into shape.

This content is for Subscribers only

To access full Breakingviews.com content you must be a subscriber. Please use the following link to request a trial.

 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)